Alnylam Pharmaceuticals Inc (ALNY)vsHCW Biologics Inc (HCWB)
ALNY
Alnylam Pharmaceuticals Inc
$303.05
-0.19%
HEALTHCARE · Cap: $37.76B
HCWB
HCW Biologics Inc
$1.79
-13.53%
HEALTHCARE · Cap: $11.67M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 64930% more annual revenue ($4.29B vs $6.59M). ALNY leads profitability with a 12.6% profit margin vs -34.7%. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
HCWB
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.4%
Fair Value
$2372.19
Current Price
$303.05
$2069.14 discount
Intrinsic value data unavailable for HCWB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Strong operational efficiency at 49.4%
Revenue surging 129081.0% year-over-year
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 37.6x book value
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : HCWB
The strongest argument for HCWB centers on Operating Margin, Revenue Growth, Price/Book. Revenue growth of 129081.0% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 70.9x leaves little room for execution misses.
Bear Case : HCWB
The primary concerns for HCWB are EPS Growth, Market Cap, Debt/Equity.
Key Dynamics to Monitor
ALNY profiles as a growth stock while HCWB is a hypergrowth play — different risk/reward profiles.
HCWB carries more volatility with a beta of 1.14 — expect wider price swings.
HCWB is growing revenue faster at 129081.0% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 43/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
HCW Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
HCW Biologics Inc is a pioneering biotechnology firm focused on advancing immunotherapies and vaccine technologies to tackle critical health issues like cancer and infectious diseases. By utilizing proprietary platforms designed to optimize immune response, the company is developing a promising pipeline of clinical candidates that aim to revolutionize patient treatment. With strategic partnerships and a dedication to fulfilling unmet medical needs, HCW Biologics stands at the forefront of the biotechnology industry, representing a compelling investment opportunity amid the sector's growth.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?